MedPath

Effects of Erand mul arka eye drop on simple allergic conjunctivitis.

Phase 2
Conditions
Health Condition 1: H103- Unspecified acute conjunctivitis
Registration Number
CTRI/2022/05/042345
Lead Sponsor
Vivek P Harne
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1)Both male and female

2)Between the age group of 18 to 60 yrs will be included in the study.

3)Patient suffering from Toda (pricking pain), Sangharsh (foreign body sensation), Vishushk Bhav (dryness feeling), Shishirasruta (cline/watery discharge), Alpashopha (mild chemosis) will be selected irrespective of their sex, education, socio economic status & religion.

Exclusion Criteria

1)Patient not willing for trial

2)Pregnant & lactating women.

3)Patient who need surgical and other in intervention.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
to see effect of Erand Mul Arka Eye drop and Olopetadine 0.1 % Eye drop in Vataj Abhi Shyand (simple allergic conjunctivitis)To review ancient literature on Vataj Abhi Shyand (simple allergic conjunctivitis) <br/ ><br>Timepoint: 7th and 15th days
Secondary Outcome Measures
NameTimeMethod
evidence base support for the effect of Erand Mul Eye Drop as mentioned in our ancient literature <br/ ><br> provide simple and effective treatment for Vataj Abhi Shyand (simple allergic conjunctivitis) <br/ ><br>Timepoint: throught study for 15 days
© Copyright 2025. All Rights Reserved by MedPath